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DOI 10.1016/j.chembiol.2010.05.006That fighting bacteria is tough should
come as no surprise. After all, bacteria
outnumber humans by an estimated
billion trillion to one and reproduce half-
a-million times faster than we do. Evolu-
tion is on their side. Nonetheless, the
speed with which resistant bacteria
emerge to defeat even themost advanced
antibiotics is stunning. And it is not
just methicillin-resistant Staphylococcus
aureus (MRSA), with its estimated an-
nual toll of 100,000 deaths in the U.S.,
that causes concern. Multidrug resistant
(MDR)Pseudomonas,Acinetobater,Kleb-
siella, and other organisms are infecting
patients in increasing numbers just when
the pipeline of drugs to fight them seems
to be drying out. ‘‘Antibiotic resistance isDrug resistance is the natural and inevitable state for bacteria.a continually emerging and extremely
serious global health crisis,’’ says James
Hughes, M.D., president-elect of the
Infectious Diseases Society of America
and professor of medicine and public
health at Emory University. ‘‘We urgently
need to develop an adequate and effec-
tive antibiotic armamentarium to deal
with it.’’
In the absence of such a resource, anti-
biotic resistance exacts a heavy toll from
patients and society. In a resistant infec-
tion, physicians may need to rely on
second- and third-line drugs that typically
cost more but are less effective and more
toxic than the standard treatment for
the corresponding susceptible infection.
Robert Weinstein, M.D., who heads the
division of infectious diseases at Chica-
go’s Stroger Hospital, estimates that
a resistant bacterium on average doubles
the cost of care and the risk of dying.
Further, when such a patient gets care
in a hospital setting, the bacteria may
spread to others by unsanitized hands
and medical devices such as ventilatorsand catheters. ‘‘While we are waiting
for pharmacological bailouts, we can pre-
vent 80% or more of hospital infections
simply by using better asepsis,’’ Wein-
stein says. The need for better hand and
device hygiene is particularly dire in inten-
sive care units, with their sick patients,
intense pressure, and hectic pace. ‘‘The
busier the environment, the more the
lapses in hygiene,’’ he says. ‘‘That’s why
the epicenter of antibiotic resistance is
the ICU.’’
However, even if we adopted the best
clinical practices—and even stopped
using antibiotics altogether—resistance
will not disappear. As users of antibiotics,
humans lag far behind bacteria, fungi, and
plants that have been fighting each otherwith and defending against these power-
ful chemicals for eons. A 2006 study
of 500 spore-forming soil bacteria by
a team led by McMaster University
chemist Gerard Wright, Ph.D., found that
all of the microbes were resistant to
multiple drugs. The bugs resisted 7–8
compounds on average from a panel of
21. No drug escaped unresisted, not
even synthetic antibiotics such as cipro-
floxacin and others specifically designed
to combat resistance. Other studies note
that MDR is not a recent phenomenon;
for instance, resistance to erythromycin
is estimated to have originated 880million
years ago, while resistance to penicillin
may date back almost two billion years,
predating even the split of bacteria into
Gram-positive and Gram-negative varie-
ties. ‘‘Drug resistance is the natural and
inevitable state for bacteria,’’ says Wright.
‘‘We should think of it as a part of bio-
logical and chemical diversity, not as
episodes in an ICU.’’
Resistance can be generic or specific.
Most bacteria have efflux mechanismsChemistry & Biology 17, May 28, 2010that pump out antibiotics and other toxic
molecules before they have had time
to act. Gram-negative species possess
a cell wall that blocks most drugs. The
opportunistic water-dwelling pathogen
Pseudomonas, in particular, has a notori-
ously impenetrable cell wall and mem-
brane barrier as well as a devilishly effec-
tive set of efflux pumps. Other defense
mechanisms respond to specific modes
of attack. To neutralize b-lactam-based
drugs such as penicillin that inhibit cell
wall synthesis, bacteria have learned to
make an astonishing variety of b-lacta-
mases. To evade quinolones, ansamy-
cins, and other RNA or DNA synthesis
inhibitors, bacteria mutate to change the
molecular target. The pinnacle of evasion
may very well be resistance to glycopep-
tides such as vancomycin, which involves
a delicate and precise orchestration of
five genes to alter a cell wall component
previously believed to be mutation-proof.
‘‘If you look at the different types of resis-
tance, you see a gradient of complexity,’’
says Wright. ‘‘It ranges from a single
mutation that can detoxify an antibiotic
to elaborate selection of gene clusters
that can completely alter the molecular
target.’’
Since bacteria routinely swap genes
with one another, clinical pathogens
under selective pressure from antibiotics
quickly pick up resistance genes from
the environmental ‘‘resistome.’’ Overuse
andmisuse of antibiotics both in medicine
and other settings such as animal
farms and fishponds aggravates this
problem. All of this has led to the present
crisis, which couldn’t comeat aworse time
for the medical community. The optimism
of the 1945–1960 ‘‘Golden Era’’ of antibi-
otics, when most of the existing antibiotic
drug classes were discovered, has faded;
since then, very few new classes of antibi-
oticshave reached themarket, andmostof
the new approved drugs have been
existing molecules tailored to combat re-
sistance—an incremental approach thatª2010 Elsevier Ltd All rights reserved 413
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Ideally, new drugs should hit targets ‘‘that
don’t have an overlapping resistance
spectrum with existing targets,’’ says
Michael Fischbach, Ph.D., of theUniversity
of California in San Francisco. ‘‘We need
newscaffolds,not justfifthandsixthgener-
ation cephalosporin or penicillin.’’
Unfortunately, as pharmaceutical com-
panies have found, this is easier said than
done. Advances in sequencing bacterial
genomes in the early 1990s led to prema-
ture hopes of finding new drug targets. A
massive, costly effort by GlaxoSmithKline
from 1995 to 2001 involving 70 high-
throughput screens of nearly half-a-
million compounds against more than
300 potential genomic targets yielded
not a single usable drug. Similar efforts
at other companies have also mostly
failed. This repeated failure has driven
most pharmaceutical companies away
from antibiotic discovery, which has led
to some unfair criticism of their priorities.
‘‘People say that Big Pharma lost interest
in antibiotics because it is not economi-
cally attractive, but that’s false’’ says
Thomas Gootz, Ph.D., an antimicrobials
consultant who retired last year after
25 years at Pfizer’s antimicrobial research
and development group. ‘‘The fact is that
many companies made a huge effort, but
it was very, very nonproductive in finding
new leads.’’
There are many reasons for this failure.
Many initially promising compounds turn
out to have too narrow a spectrum to be
clinically useful (and commercially viable).
Other compounds show unacceptable
toxicity for mammalian cells or lack
drug-like properties. But the biggest
problem is to get the drug into the target
bacterium and keep it there. ‘‘In Gram-
negative bacteria, you have to get the
drug past two membranes with different
sieving properties,’’ says former Merck
researcher Lynn Silver, Ph.D., now an
antimicrobials commentator and consul-
tant. ‘‘And even when you get it inside,
you have the efflux pump to deal with.’’
Silver notes that there are no rules for
getting compounds into bacteria analo-414 Chemistry & Biology 17, May 28, 2010 ªgous to Lipinski’s rules for predicting
the drug-likeness of molecules. ‘‘In the
absence of that, the best bet for Gram-
negatives is to aim for targets outside
the cell,’’ she says. ‘‘If your target is
located inside the cell in Pseudomonas,
good luck.’’
To counteract influx barriers and efflux,
antibiotics often need to be present in the
blood at much higher levels than most
other drugs. ‘‘We typically need micro-
grams per milliliter concentration inside
the body, even if the drug has nanomolar
potency against the target,’’ says Molly
Schmid, Ph.D., a molecular biologist at
the Keck Graduate Institute of Applied
Life Sciences, who has extensive industry
experience in antimicrobials. ‘‘Finding a
drug with an acceptable level of safety is
challenging.’’ The economics of antibiotic
discovery are equally daunting. Unlike
drugs for chronic conditions such as
hypertension or diabetes, antibiotics are
used only for short periods. Further, only
a small fraction of infections involve
resistant organisms, limiting the market
for newer and often more expensive
compounds. Finally, unlike most medica-
tions, the useful shelf-life of a new antibi-
otic may be limited to the few years it
takes for resistance to become wide-
spread. The combination of these factors
may lead to poor return on investment. On
top of that, the FDA has toughened its
regulatory stance on antibiotics in recent
years, according to industry experts.
‘‘Discovering any drug is hard, but dis-
covering antibiotics is even harder,’’
says Schmid. ‘‘The market and regulatory
bars for new antibiotics are so high that
if we discovered penicillin today, we
almost certainly could not get it to the
market.’’
Despite these obstacles, antibacterial
research continues at many small compa-
nies. Lexington, Massachusetts-based
Cubist has several compounds in its pipe-
line, including one that combines a b-lac-
tamase inhibitor with a fifth generation
cephalosporin. ‘‘Its spectrum, potency,
and lack of resistance development is
extraordinarily good against Pseudo-2010 Elsevier Ltd All rights reservedmonas,’’ says Cubist’s head of scientific
affairs, Barry Eisenstein, M.D. Watertown,
Massachusetts-based Tetraphase is
using a new, fully synthetic method of
generating tetracycline to develop new
molecules of this class. ‘‘We’re able to
change the bulky tetracycline molecule
at every position, something that was
unheard of before,’’ says Joyce Sutcliffe,
Ph.D., the company’s senior vice presi-
dent for biology. ‘‘We can now unlock the
full potential of this class of antibiotics.’’
Some in academia, such as Rockefeller
Institute researcher Vincent Fischetti,
Ph.D., are looking at alternatives to tradi-
tional antibiotics. ‘‘Bacteria laugh at us
when we throw an antibiotic at them,’’ he
says. ‘‘Within a fewmonths they’ve figured
it out.’’ Instead, he suggests that we
learn from bacteriophages, long-term
predators of bacteria that use a variety
of lytic enzymes to break out of a cell
they’ve infected and proliferated within.
One such enzyme identified by Fischetti’s
group turns out to be very effective
against anthrax and other Gram-positive
microbes. ‘‘Phages have figured out by
trial and error which are the substrates
bacteria can’t change,’’ says Fischetti.
‘‘We can thus use nature against nature.’’
Antivirulence—pacifying rather than kill-
ing bacteria—is another strategy. Tufts
University researcher Naomi Balaban,
Ph.D., has developed a compound that
interferes with quorum sensing by bac-
teria and prevents them from forming
biofilms. Stuart Levy, M.D., also from
Tufts, whose pioneering work led to the
discovery of the ‘‘mar’’ proteins in many
bacteria that regulate genes involved in
infection, now leads an effort at Boston-
based Paratek to develop compounds
that inhibit these proteins. ‘‘The cell can
then sit there and live, but since it can’t
turn on these genes, it can’t cause an
infection,’’ Levy says. ‘‘It’s a whole novel
paradigm: don’t kill the bacteria, instead
hold them in check and prevent an
infection.’’Chandra Shekhar (chandra@nasw.org) is a science
writer based in Princeton, NJ.
